Evaluation of trichodynia (hair pain) during chemotherapy or tamoxifen treatment in breast cancer patients

Kanti, Varvara; Nuwayhid, R.; Lindner, Judith; Hillmann, Kathrin; Bangemann, Nikola; Kleine-Tebbe, A.; Blume-Peytavi, Ulrike; Bartels, Natalie Garcia

doi:10.1111/jdv.13396

Cited by 9 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More studies have been published since then, describing a prevalence that varies between 17 and 35.7% of individuals with hair loss [19,23]. It has been classically described in cases of TE and AGA [19,[24][25][26], but also reported in cicatricial alopecias, AA, trichotillomania, and chemotherapyinduced alopecia [6,23,[27][28][29][30].…”

Section: Clinical Manifestations and Trichodyniamentioning

confidence: 99%

Sensitive Scalp and Trichodynia: Epidemiology, Etiopathogenesis, Diagnosis, and Management

Souza,

Anzai,

Fechine

et al. 2023

Skin Appendage Disord

View full text Add to dashboard Cite

Sensitive scalp (SSc) is considered a sensitive skin on the scalp, with its particularities. Although it is not rare in the dermatological practice and the term is commonly present in personal care products, this entity is poorly investigated in the medical literature. The etiopathogenesis is still uncertain, and the sensitivity may be associated with hair loss. Clinical manifestations are subjective symptoms of pruritus, burning, pain, pricking, and/or trichodynia, often with scalp erythema. SSc can be triggered by several factors (endogenous or exogenous). The diagnosis is guided by the anamnesis, and there are still no specific trichoscopic features. Trigeminal trophic syndrome and postherpetic neuralgia are the main differential diagnosis to be considered. We organized the therapeutical approach in three steps: scalp care, topical and systemic treatment.

show abstract

Section: Clinical Manifestations and Trichodyniamentioning

confidence: 99%

Sensitive Scalp and Trichodynia: Epidemiology, Etiopathogenesis, Diagnosis, and Management

Souza,

Anzai,

Fechine

et al. 2023

Skin Appendage Disord

View full text Add to dashboard Cite

show abstract

“…Evaluation of trichodynia (hair pain) during chemotherapy or tamoxifen treatment in breast cancer patients [26] Chemotherapy has more severe hair loss and scalp pain compared to Tamoxifen, and the duration is also longer.…”

Section: / Kanti/2015mentioning

confidence: 99%

Toward a Value-Based Therapy Recommendation Model

Liu,

Xiao

2023

Healthcare

View full text Add to dashboard Cite

Patient value is an important factor in clinical decision making, but conventionally, it is not incorporated in the decision processes. Clinical decision making has some clinical guidelines as a reference. There are very few value-based clinical guidelines, but knowledge about how values affect decision making is mentioned in some scattered studies in the literature. We use a literature review method to extract evidence and integrate it as part of the decision-making model. In this paper, a value-based therapy recommendation comprehensive model is proposed. A literature analysis is conducted to collect value-based evidence. The patients’ values are defined and classified with fine granularity. Categorized values and candidate therapies are used in combination as filtering keywords to build this literature database. The literature analysis method generates a literature database used as a source of arguments for influencing decision making based on values. Then, a formalism model is put forward to integrate the value-based evidence with clinical evidence, and the literature databases and clinical guidelines are collected and analyzed to populate the evidence repository. During the decision-making processes, the evidence repository is utilized to match patients’ clinical information and values. Decision-makers can dynamically adjust the relative importance of the two pieces of evidence to obtain a treatment plan that is more suitable for the patient. A prototype system was implemented using a case study for breast cancer and validated for feasibility and effectiveness through controlled experiments.

show abstract

“…Dermatologists as well often fail to deliver reliable data, as Tosti et al [6] properly pointed out. According to Tallon et al [7], for example, the histopathology of PA does not reveal any inflammatory sign, while scarring alopecias have been described [2] quite probably resulting from inflammation, and trichodynia [8], which may depend on peribulbar inflammation, has been reported in up to 87% of cases [9]. Indeed, apparently, irrespective of the quality and dose of the employed drugs, not all the treated patients complain of hair loss.…”

Section: Doi: 101159/000514342mentioning

confidence: 99%

Why Do Not All Chemotherapy Patients Lose Their Hair? Answering an Intriguing Question

Rebora

Guarrera²

2021

Skin Appendage Disord

View full text Add to dashboard Cite

Evaluation of trichodynia (hair pain) during chemotherapy or tamoxifen treatment in breast cancer patients

Cited by 9 publications

References 35 publications

Sensitive Scalp and Trichodynia: Epidemiology, Etiopathogenesis, Diagnosis, and Management

Sensitive Scalp and Trichodynia: Epidemiology, Etiopathogenesis, Diagnosis, and Management

Toward a Value-Based Therapy Recommendation Model

Why Do Not All Chemotherapy Patients Lose Their Hair? Answering an Intriguing Question

Contact Info

Product

Resources

About